Adverse outcomes in patients with venous thromboembolic disease from a rural population.
OBJECTIVE
To study the adverse outcomes and its predictors during anticoagulant therapy in patients with venous thromboembolic disease (VTD) from a rural population.


METHODS
This is a prospective observational study of 94 consecutive patients. The patients were diagnosed in a first-level hospital from a rural Spanish area using objective methods of VTD.


RESULTS
The mean follow-up with anticoagulant therapy was 7.1 months (range: 0-29 months). Eighteen patients (19.1%) had an adverse outcome: 10 (10.6%) during the first month and 8 (8.5%) after the first month. Sixteen patients (17%) died, 6 (6.4%) had a major hemorrhage, and 4 (4.3%) had a thromboembolic recurrence. Comorbidity, cancer, nonidiopathic VTD, and pulmonary thromboembolism were significantly associated with adverse outcomes.


CONCLUSIONS
Adverse outcomes during anticoagulant therapy are frequent in patients from a rural population with VTD. These adverse outcomes occur frequently during the first month of treatment and are associated with the patient's prior status and the presence of pulmonary thromboembolism.
Calvo-Romero
José María
JM
Internal Medicine Service, Hospital Ciudad de Coria; and Family Medicine, Area de Salud de Coria (Cáceres), Spain. jmcalvo@orangemail.es
Lima-Rodríguez
Esther María
EM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D002423:Cause of Death; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000139:chemically induced / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000401:mortality*; D012008:Recurrence; D012307:Risk Factors; D012424:Rural Population / Q000706:statistics & numerical data*; D013030:Spain; D016019:Survival Analysis; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000401:mortality*
D000925:Anticoagulants